Welcome to STN International! Enter x:X

LOGINID:SSPTASMR1614

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * Welcome to STN International * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	DEC 01	ChemPort single article sales feature unavailable
NEWS 3	FEB 02	Simultaneous left and right truncation (SLART) added for CERAB, COMPUAB, ELCOM, and SOLIDSTATE
NEWS 4	FEB 02	GENBANK enhanced with SET PLURALS and SET SPELLING
NEWS 5	FEB 06	Patent sequence location (PSL) data added to USGENE
NEWS 6	FEB 10	COMPENDEX reloaded and enhanced
NEWS 7	FEB 11	WTEXTILES reloaded and enhanced
NEWS 8	FEB 19	New patent-examiner citations in 300,000 CA/CAplus patent records provide insights into related prior art
NEWS 9	FEB 19	Increase the precision of your patent queries -- use terms from the IPC Thesaurus, Version 2009.01
NEWS 10	FEB 23	Several formats for image display and print options discontinued in USPATFULL and USPAT2
NEWS 11	FEB 23	MEDLINE now offers more precise author group fields and 2009 MeSH terms
NEWS 12	FEB 23	TOXCENTER updates mirror those of MEDLINE - more precise author group fields and 2009 MeSH terms
NEWS 13	FEB 23	Three million new patent records blast AEROSPACE into STN patent clusters
NEWS 14	FEB 25	USGENE enhanced with patent family and legal status display data from INPADOCDB
NEWS 15	MAR 06	INPADOCDB and INPAFAMDB enhanced with new display formats
NEWS 16	MAR 11	EPFULL backfile enhanced with additional full-text applications and grants
NEWS 17	MAR 11	ESBIOBASE reloaded and enhanced
NEWS 18	MAR 20	CAS databases on STN enhanced with new super role for nanomaterial substances
NEWS 19	MAR 23	CA/CAplus enhanced with more than 250,000 patent equivalents from China
NEWS 20	MAR 30	IMSPATENTS reloaded and enhanced
NEWS 21	APR 03	CAS coverage of exemplified prophetic substances enhanced
NEWS 22	APR 07	STN is raising the limits on saved answers
NEWS 23	APR 24	CA/CAplus now has more comprehensive patent assignee information
NEWS 24	APR 26	USPATFULL and USPAT2 enhanced with patent assignment/reassignment information
NEWS 25	APR 28	CAS patent authority coverage expanded
NEWS 26	APR 28	ENCOMPLIT/ENCOMPLIT2 search fields enhanced
NEWS 27	APR 28	Limits doubled for structure searching in CAS REGISTRY

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items

```
Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN customer
  agreement.  This agreement limits use to scientific research.  Use
  for software development or design, implementation of commercial
  gateways, or use of CAS and STN data in the building of commercial
  products is prohibited and may result in loss of user privileges
  and other penalties.

* * * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 09:45:52 ON 07 MAY 2009

=> file reg
COST IN U.S. DOLLARS                                 SINCE FILE      TOTAL
                                                        ENTRY    SESSION
FULL ESTIMATED COST                                      0.22       0.22

FILE 'REGISTRY' ENTERED AT 09:46:05 ON 07 MAY 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:    5 MAY 2009  HIGHEST RN 1143038-16-7
DICTIONARY FILE UPDATES:   5 MAY 2009  HIGHEST RN 1143038-16-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\STNEXP\Queries\10579288.str

L1      STRUCTURE UPLOADED

=> s l1 sss full
FULL SEARCH INITIATED 09:46:23 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -    43491 TO ITERATE

100.0% PROCESSED    43491 ITERATIONS                                3 ANSWERS
SEARCH TIME: 00.00.01

L2            3 SEA SSS FUL L1

=> d l2
```

L2 ANSWER 1 OF 3 REGISTRY COPYRIGHT 2009 ACS on STN
RN 960298-66-2 REGISTRY
ED Entered STN: 10 Jan 2008
CN 2(1H)-Pyridinone, 1-(3-fluoro-4-hydroxyphenyl)-4-methyl- (CA INDEX NAME)
OTHER NAMES:
CN 1-(3-Fluoro-4-hydroxyphenyl)-4-methylpyridin-2(1H)-one
MF C12 H10 F N O2
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	187.93	188.15

FILE 'CAPLUS' ENTERED AT 09:46:36 ON 07 MAY 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 7 May 2009 VOL 150 ISS 19
FILE LAST UPDATED: 6 May 2009 (20090506/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Feb 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Feb 2009

CAplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate

```
=> s l2
L3            3 L2

=> d l2 1-3 ibib ab
YOU HAVE REQUESTED DATA FROM FILE 'REGISTRY' - CONTINUE? (Y)/N:n


=> file caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.50     188.65

FILE 'CAPLUS' ENTERED AT 09:46:58 ON 07 MAY 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 7 May 2009  VOL 150 ISS 19
FILE LAST UPDATED: 6 May 2009  (20090506/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED:  Feb 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE:  Feb 2009

CAplus now includes complete International Patent Classification (IPC)
reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate

=> s l2
L4            3 L2

=> d l4 1-2 ibib ab

L4   ANSWER 1 OF 3  CAPLUS  COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER:         2007:1454807  CAPLUS
DOCUMENT NUMBER:          148:78895
TITLE:                    Preparation of quinoline derivatives as tyrosine
                          kinases inhibitors
INVENTOR(S):              Gaudino, John; Boyd, Steven Armen; Marlow, Allison L.;
                          Kaplan, Tomas; Fong, Kin Chiu; Seo, Jeongbeob; Tian,
                          Hongqi; Blake, James; Koch, Kevin
PATENT ASSIGNEE(S):       Array Biopharma Inc., USA; Genentech, Inc.
SOURCE:                   PCT Int. Appl., 189pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
```

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007146824	A2	20071221	WO 2007-US70787	20070608
WO 2007146824	A3	20080410		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
CA 2655128	A1	20071221	CA 2007-2655128	20070608
EP 2032538	A2	20090311	EP 2007-798333	20070608
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS				
IN 2008KN05043	A	20090327	IN 2008-KN5043	20081211
PRIORITY APPLN. INFO.:			US 2006-811909P	P 20060608
			WO 2007-US70787	W 20070608

OTHER SOURCE(S): MARPAT 148:78895

AB Title compds. represented by the formula I [wherein R1, R2, R4 = independently H, halo, CN, etc.; with the proviso that at least one of R1 and R2 is not H; L = (un)substituted (hetero)cyclyl or (hetero)aryl; R5 = -COH, (un)substituted amino, heterocyclyl, etc.; and stereoisomers, geometric isomers, tautomers, solvates, metabolites, and salts thereof] were prepared as tyrosine kinases inhibitors. For example, II was provided in a multi-step synthesis starting from the reaction of (2-methylbenzyl)zinc chloride with 4,6-dichloro-5-methylpyrimidine. Certain compds. of this invention had MKN45 cell-based activity IC50 values less than 100 nM. Thus, I and their pharmaceutical compns. are useful for inhibiting receptor tyrosine kinases and for treating hyperproliferative disorders mediated thereby.

L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2006:47365 CAPLUS
DOCUMENT NUMBER: 144:274114
TITLE: Synthesis of N-substituted 4,6-dimethyl-3-cyano-2-pyridones under microwave irradiation
AUTHOR(S): Mijin, Dusan; Marinkovic, Aleksandar
CORPORATE SOURCE: Department of Organic Chemistry, Faculty of Technology and Metallurgy, University of Belgrade, Belgrade,
SOURCE: Synthetic Communications (2006), 36(2), 193-198
CODEN: SYNCAV; ISSN: 0039-7911
PUBLISHER: Taylor & Francis, Inc.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 144:274114

AB N-substituted 4,6-dimethyl-3-cyano-2-pyridones were prepared from acetylacetone, N-substituted cyanoacetamide, and piperidine as catalyst under microwave irradiation without solvent. The rapid and simple method produced pure products in high yields.

REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> file reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     9.00     197.65

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                    -1.64      -1.64

FILE 'REGISTRY' ENTERED AT 09:50:41 ON 07 MAY 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:    5 MAY 2009  HIGHEST RN 1143038-16-7
DICTIONARY FILE UPDATES:   5 MAY 2009  HIGHEST RN 1143038-16-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\STNEXP\Queries\10579288 str 2.str

L5      STRUCTURE UPLOADED

=> s l5 sss ful
FULL SEARCH INITIATED 09:50:57 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -    11746 TO ITERATE

100.0% PROCESSED    11746 ITERATIONS                                 4 ANSWERS
SEARCH TIME: 00.00.01

L6            4 SEA SSS FUL L5

=> file caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                   185.88     383.53

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                     0.00      -1.64

FILE 'CAPLUS' ENTERED AT 09:51:05 ON 07 MAY 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
```

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 7 May 2009 VOL 150 ISS 19
FILE LAST UPDATED: 6 May 2009 (20090506/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Feb 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Feb 2009

CAplus now includes complete International Patent Classification (IPC)
reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate

=> s l6
L7 7 L6

=> d l7 1-7 ibib ab

L7 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2008:805359 CAPLUS
DOCUMENT NUMBER: 149:119686
TITLE: Use of pyridone derivatives in the prevention or treatment of tissue or organ toxicity induced by cytotoxic agents and radiation
INVENTOR(S): Wu, Jun; Luo, Ying; Zhou, Tieling
PATENT ASSIGNEE(S): Peop. Rep. China
SOURCE: U.S. Pat. Appl. Publ., 18pp., Cont.-in-part of Appl. No. PCT/CN2006/002504.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20080161361	A1	20080703	US 2007-958353	20071217
WO 2007147297	A1	20071227	WO 2006-CN2504	20060925

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,

IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2006-804914P P 20060615
WO 2006-CN2504 A2 20060925

OTHER SOURCE(S): MARPAT 149:119686

AB The present invention is directed to a novel use of pyridone derivs. such as pirfenidone for the prevention and treatment of damages to tissues or organs induced by various cytotoxic agents, such as chemotherapeutic agents, biologics, immunosuppressants and radiation. Such prophylactic and/or therapeutic effects of the pyridone derivs. make it possible to increase therapeutic dosages of the cytotoxic agent, thereby enhancing the therapeutic efficacy of the cytotoxic agent and radiation therapy.

L7 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2008:691547 CAPLUS
DOCUMENT NUMBER: 149:104353
TITLE: 13C- and 1H-NMR substituent-induced chemical shifts in N(1)-(4-substituted phenyl)-3-cyano-4,6-dimethyl-2-pyridones
AUTHOR(S): Marinkovic, Aleksandar D.; Valentic, Natasa V.; Mijin, Dusan Z.; Uscumlic, Gordana G.; Jovanovic, Bratislav Z.
CORPORATE SOURCE: Department of Organic Chemistry, Faculty of Technology and Metallurgy, University of Belgrade, Belgrade, 11120,
SOURCE: Journal of the Serbian Chemical Society (2008), 73(5), 513-524
CODEN: JSCSEN; ISSN: 0352-5139
PUBLISHER: Serbian Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The 13C- and 1H-NMR chemical shifts of thirteen N(1)(4-substituted phenyl)-3-cyano-4,6-dimethyl-2-pyridones were measured in deuterated DMSO (DMSO-d6). The correlation anal. for the substituent-induced chemical shifts (SCS) with σp, inductive (σI) and different scale of resonance (σR) parameters were performed using the SSP (single substituent parameter), DSP (dual substituent parameter) and DSP-NLR (dual substituent parameter-nonlinear resonance) methods. The results of the calcns. concerning the polar and resonance effects satisfactorily describe the substituent effects at the carbon atoms of interest. The mode of transmission of the substituent effects, both inductive and resonance, in relation to the geometry of the studied pyridones is discussed.

REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2007:593497 CAPLUS
DOCUMENT NUMBER: 147:23753
TITLE: Therapeutic compounds for modulating stress-activated protein kinase system in treatment of inflammatory or fibrotic disease
INVENTOR(S): Seiwert, Scott D.; Kossen, Karl; Serebryany, Vladimir
PATENT ASSIGNEE(S): Intermune, Inc., USA
SOURCE: PCT Int. Appl., 98pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007062167	A2	20070531	WO 2006-US45287	20061122
WO 2007062167	A9	20070726		
WO 2007062167	A3	20071115		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
AU 2006318428	A1	20070531	AU 2006-318428	20061122
CA 2630752	A1	20070531	CA 2006-2630752	20061122
EP 1960405	A2	20080827	EP 2006-844534	20061122
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS				
JP 2009517390	T	20090430	JP 2008-542451	20061122
IN 2008DN04358	A	20080815	IN 2008-DN4358	20080522
MX 2008006688	A	20080730	MX 2008-6688	20080523
KR 2008076968	A	20080820	KR 2008-715085	20080620
CN 101360750	A	20090204	CN 2006-80051489	20080721
PRIORITY APPLN. INFO.:			US 2005-739315P P	20051123
			US 2006-775823P P	20060221
			US 2006-793526P P	20060420
			WO 2006-US45287 W	20061122

OTHER SOURCE(S): MARPAT 147:23753

AB It has now been discovered that a high therapeutic effect in treating various disorders associated with enhanced activity of a stress-activated protein kinase (SAPK) system may be achieved by using a potent p38γ kinase inhibitor compound which also has inhibitory activity against p38α. Furthermore, reducing the activities of both kinase p38γ and kinase p38α without reducing the activity of a kinase p38α to such an extent that undesired side effects are observed upon administration to a subject having a disorder associated with enhanced activity of kinase p38 has been discovered to be achievable by modifying inhibitors of p38α such that the modification engenders inhibitory activity against p38γ. Described are bicyclic oxopyridine derivs. and analogs, pyrimidinyl imidazole derivs. and analogs, and diacyl urea compds. with activity against p38γ and p38α. Sixteen compds. of general structure I (R1 = H, OH, OCH3, COCH3; R2 = H, CH3, glucuronide, CH2OCH3, Br, CH2F3, CO2CH3; R3 = H, OH; Z = O, S) have IC50 values of 200-8700 and 15-1600 μM, resp., for p38α and p38γ. Disclosed are methods of using described compds. and compns. to modulate a SAPK system with an active compound, wherein the active compound exhibits inhibition of the p38γ and p38α mitogen-activated protein kinases (MAPKs). Also disclosed are methods for identifying compds. which inhibit p38α and p38γ MAPKs and which can modulate a SAPK system.

L7 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2007:512041 CAPLUS

DOCUMENT NUMBER: 146:475698

TITLE: Methods for treating atrial fibrillation with p38 MAP

kinase inhibitors
INVENTOR(S): Olgin, Jeff; Eisenberg, Susan; Blatt, Lawrence M.; Seiwert, Scott; Kossen, Karl
PATENT ASSIGNEE(S): Intermune, Inc., USA; The Regents of the University of California
SOURCE: PCT Int. Appl., 79pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007053685	A2	20070510	WO 2006-US42653	20061101
WO 2007053685	A3	20070719		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
CA 2627547	A1	20070510	CA 2006-2627547	20061101
EP 1948178	A2	20080730	EP 2006-836759	20061101
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
JP 2009513713	T	20090402	JP 2008-538997	20061101
PRIORITY APPLN. INFO.:			US 2005-732676P P	20051101
			WO 2006-US42653 W	20061101

OTHER SOURCE(S): MARPAT 146:475698
AB The invention discloses p38 MAP kinase inhibitor compds. and methods useful in treating or preventing atrial fibrillation (AF). Preparation of e.g. 1-(4-hydroxyphenyl)-5-(trifluoromethyl)-2-pyridone is described.

L7 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2006:1206139 CAPLUS
DOCUMENT NUMBER: 145:500150
TITLE: Method of modulating stress-activated protein kinase system
INVENTOR(S): Blatt, Lawrence M.; Seiwert, Scott D.; Beigelman, Leonid; Radhakrishnan, Ramachandran
PATENT ASSIGNEE(S): Intermune, Inc., USA
SOURCE: PCT Int. Appl., 99pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006122154	A2	20061116	WO 2006-US17988	20060509
WO 2006122154	A3	20070726		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,				

GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR,
KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX,
MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE,
SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC,
VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

AU 2006244072	A1	20061116	AU 2006-244072		20060509
AU 2006244072	A2	20090326			
CA 2608116	A1	20061116	CA 2006-2608116		20060509
US 20060270612	A1	20061130	US 2006-431132		20060509
EP 1928454	A2	20080611	EP 2006-759440		20060509

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL,
BA, HR, MK, YU

JP 2008544743	T	20081211	JP 2008-511290		20060509
NO 2007005646	A	20071207	NO 2007-5646		20071106
IN 2007DN08551	A	20080627	IN 2007-DN8551		20071106
MX 2007014114	A	20080314	MX 2007-14114		20071109
KR 2008023680	A	20080314	KR 2007-728127		20071130
CN 101237869	A	20080806	CN 2006-80025160		20080110
PRIORITY APPLN. INFO.:			US 2005-679471P	P	20050510
			US 2005-732230P	P	20051101
			WO 2006-US17988	W	20060509

OTHER SOURCE(S): MARPAT 145:500150

AB Disclosed are methods of modulating a stress activated protein kinase (SAPK) system with an active compound, wherein the active compound exhibits low potency for inhibition of at least one p38 MAPK; and wherein the contacting is conducted at a SAPK-modulating concentration that is at a low percentage inhibitory concentration for inhibition of the at least one p38 MAPK by the compound Also disclosed are derivs. of pirfenidone. These derivs. can modulate a stress activated protein kinase (SAPK) system. Another embodiment of the present invention is a method of treating or preventing a disease state in a subject, including, identifying a subject at risk for or having a condition selected from an inflammatory condition and a fibrotic condition; administering a compound to the subject in an effective amount to treat or prevent the condition.

L7 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2005:451359 CAPLUS
DOCUMENT NUMBER: 142:463616
TITLE: Derivatives of pyridones and their applications
INVENTOR(S): Yi, Xianghui
PATENT ASSIGNEE(S): Peop. Rep. China
SOURCE: PCT Int. Appl., 22 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Chinese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005047256	A1	20050526	WO 2003-CN968	20031114

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE,
GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,
LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ,

OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,
TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2003284808	A1	20040606	AU 2003-284808		20031114
AU 2003284808	B2	20090122			
CA 2545813	A1	20050526	CA 2003-2545813		20031114
EP 1683788	A1	20060726	EP 2003-773437		20031114
R: CH, DE, GB, LI					
CN 1878757	A	20061213	CN 2003-80110691		20031114
CN 100358872	C	20080102			
JP 2007510618	T	20070426	JP 2005-510535		20031114
US 20070049624	A1	20070301	US 2006-579288		20060515
IN 2006DN03353	A	20070824	IN 2006-DN3353		20060609

PRIORITY APPLN. INFO.: WO 2003-CN968 A 20031114
OTHER SOURCE(S): MARPAT 142:463616
AB N-substituted-2(1H) pyridones I (R1 = Me, Et or CF3 in the 3-, 4-, 5- or 6-position; R2 = OH, SH, SMe or SEt in the 2-, 3- or 4-position), their pharmaceutically acceptable salts, and pharmaceutical prepns. are prepared The compds. can effectively treat various fibrotic diseases such as hepatic fibrosis.
REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1993:80944 CAPLUS
DOCUMENT NUMBER: 118:80944
ORIGINAL REFERENCE NO.: 118:14245a,14248a
TITLE: Benzoxazinyl-substituted pyridone derivatives, and their production and use as herbicides
INVENTOR(S): Uekawa, Toru; Takemura, Susumu; Enomoto, Masayuki; Sakaki, Masaharu; Sato, Ryo; Nagano, Eiki
PATENT ASSIGNEE(S): Sumitomo Chemical Co., Ltd., Japan
SOURCE: Eur. Pat. Appl., 29 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
EP 488220	A2	19920603	EP 1991-120281		19911127
EP 488220	A3	19920812			
R: BE, CH, DE, FR, GB, IT, LI, NL					
US 5238906	A	19930824	US 1991-797069		19911125
JP 05170739	A	19930709	JP 1991-312487		19911127

PRIORITY APPLN. INFO.: JP 1990-326673 A 19901127
JP 1991-277691 A1 19911024
OTHER SOURCE(S): MARPAT 118:80944
AB Eleven herbicidal title compds. I (R = alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, alkoxyalkyl; X = H, halo, Me or Et with optional mono- or polyhalo substitution; Y = H, Me) were prepared For example, 1-(2-fluoro-4-hydroxy-5-nitrophenyl)-4-trifluoromethyl-2-pyridone (prepare in 4 steps) was O-alkylated by BrCH2CO2Me and NaH in DMF to give the 4-methoxycarbonylmethoxy derivative II, which was reductively cyclized by powdered Fe in aqueous AcOH to give I (R = X = Y = H). N-alkylation of this by propargyl bromide andK2CO3 in DMF gave I (R = CH2C.tplbond.CH, X = Y = H) (III). As a foliar spray at 0.16 g/are, III gave complete control (5.5)

of red root pigweed and black nightshade, good control (4.5) of velvetleaf, and low phytotoxicity (1.5) to soybean, corn, and rice.

```
=> d his

     (FILE 'HOME' ENTERED AT 09:45:52 ON 07 MAY 2009)

     FILE 'REGISTRY' ENTERED AT 09:46:05 ON 07 MAY 2009
L1             STRUCTURE UPLOADED
L2           3 S L1 SSS FULL

     FILE 'CAPLUS' ENTERED AT 09:46:36 ON 07 MAY 2009
L3           3 S L2

     FILE 'CAPLUS' ENTERED AT 09:46:58 ON 07 MAY 2009
L4           3 S L2

     FILE 'REGISTRY' ENTERED AT 09:50:41 ON 07 MAY 2009
L5             STRUCTURE UPLOADED
L6           4 S L5 SSS FUL

     FILE 'CAPLUS' ENTERED AT 09:51:05 ON 07 MAY 2009
L7           7 S L6
```